TTX Stock Overview
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Theralase Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.089 |
| 52 Week High | CA$0.19 |
| 52 Week Low | CA$0.088 |
| Beta | 1.59 |
| 1 Month Change | -10.05% |
| 3 Month Change | -3.76% |
| 1 Year Change | -45.43% |
| 3 Year Change | -41.88% |
| 5 Year Change | -72.80% |
| Change since IPO | -69.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| TTX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -13.1% | -5.0% | -2.0% |
| 1Y | -45.4% | -13.6% | -0.3% |
Return vs Industry: TTX underperformed the German Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: TTX underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| TTX volatility | |
|---|---|
| TTX Average Weekly Movement | 15.3% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TTX's share price has been volatile over the past 3 months.
Volatility Over Time: TTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Roger Dumoulin-White | www.theralase.com |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer.
Theralase Technologies Inc. Fundamentals Summary
| TTX fundamental statistics | |
|---|---|
| Market cap | €26.56m |
| Earnings (TTM) | -€3.13m |
| Revenue (TTM) | €732.82k |
36.2x
P/S Ratio-8.5x
P/E RatioIs TTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTX income statement (TTM) | |
|---|---|
| Revenue | CA$1.07m |
| Cost of Revenue | CA$508.17k |
| Gross Profit | CA$562.13k |
| Other Expenses | CA$5.13m |
| Earnings | -CA$4.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 52.52% |
| Net Profit Margin | -427.06% |
| Debt/Equity Ratio | 0% |
How did TTX perform over the long term?
See historical performance and comparison